A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

Original reporting
Published Oct 19, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$VVOS
Bullish
high confidence
Mentioned
$VVOS
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VVOSBullishHigh
01

Why it matters

The deal adds $10 M+ of equity, expands product offerings, and creates new distribution channels, but execution depends on pending agreements and bankruptcy court approval for AHA.

02

Market read

First‑report of a strategic acquisition that could improve Vivos’ balance sheet and growth outlook, offering a short‑term trading catalyst.

03

What to watch

Potential dilution from convertible preferred shares and reliance on third‑party agreements for commercialization

Relevance 7/10Novelty 8/10Timing: immediate, same‑day announcement

Background

Vivos Therapeutics (Nasdaq: VVOS) closed an acquisition of a 50% stake in a pseudohypoxia test and issued convertible preferred stock, aiming to broaden its OSA treatment portfolio.

Company-level read

Ticker impact

$VVOSBullishHigh confidence
Context

Vivos Therapeutics announced closing of its acquisition of a 50% interest in a pseudohypoxia test, adding over $10 million of stockholders’ equity and issuing Series C Convertible Preferred Stock.

Expected impact

likely upward pressure as investors price in the equity boost and new market opportunities

Evidence & confidence

First‑report of a completed acquisition with a material equity addition; no immediate dilution concerns and potential multi‑million‑dollar revenue stream pending regulatory clearance.

Market effects

expands the sleep‑apnea diagnostics sector and may spur interest in related medical‑device stocks

U.S. healthcare and med‑tech markets could see modest uplift

limited to niche sleep‑apnea market; no broad macro effect

Counterpoint

If regulatory approval stalls or the partnership fails, the equity boost may be offset by dilution and unmet revenue expectations

Key entities

  • Vivos Therapeutics, Inc.

    US‑listed med‑tech firm focusing on sleep‑apnea diagnostics and treatments

  • SOD Sciences, Inc.

    Precision‑health firm developing the ReBalU Protocol and pseudohypoxia test

Related articles

$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$DASHHighAI 9/10

DoJ To Reportedly Scrutinize DoorDash And Instacart’s $17B Merger

The U.S. Department of Justice will review DoorDash's proposed $17 billion acquisition of Instacart, valued at $65 per share, according to Reuters. The deal aims to expand DoorDash's presence in the U.S. online grocery market. DASH stock rose 0.7% after-hours, while CART stock fell $2. The transaction is expected to close by late 2027 or early 2028, pending regulatory approval.

$TUMedAI 8/10

What you need to know about a proposed Quebecor-Telus merger

Quebecor Inc. proposed a $31-billion merger with Telus, raising concerns about competition and regulatory approval. Analysts suggest the deal could reduce wireless competition, potentially increasing prices. Telus's stock has declined 32% year-to-date, making it an attractive target. The merger could face regulatory hurdles, including potential asset spin-offs.